APT(SH:688617) Haitong Securities International·2025-11-10 09:05Investment Rating - The report maintains an "Outperform" rating for the company [4][11]. Core Insights - The company continues to experience robust revenue growth, with a projected revenue of RMB 2.698 billion for 2025, reflecting a year-on-year increase of 30.6% [3][4]. - Net profit attributable to shareholders is expected to reach RMB 870 million in 2025, representing a growth of 29.2% compared to the previous year [3][4]. - The target price for the stock is set at RMB 333.05, with a target PE of 54X for 2025 [4][11]. Financial Summary - Total revenue for the first three quarters of 2025 was RMB 1.867 billion, with a net profit of RMB 623 million [4][11]. - Q3 2025 revenue was RMB 654 million, with a net profit of RMB 198 million [4][11]. - Forecasted EPS for 2025-2027 is RMB 6.17, RMB 8.09, and RMB 10.50 respectively [4][11]. Business Development - The volume of PFA surgeries is rapidly increasing, with expectations to exceed 5,000 procedures in 2025 [12][4]. - The company has expanded its promotion team to over 200 sales and on-site engineers, aiming for a 10%-20% annual increase in on-site volume per engineer [12][4]. - Increased investment in PFA promotion and R&D is evident, with Q3 2025 sales expenses at RMB 125 million and R&D expenses at RMB 98 million [13][4]. Market Position - The company holds approximately 20% market share in coronary business and over 30% in tumor intervention access products [14][4]. - Growth in the coronary and peripheral business is driven by existing product lines and the introduction of iterative products post volume-based procurement [14][4].